摘要
To the Editor： Mantle cell lymphoma （MCL） is a non-Hodgkin＇s lymphoma （NHL） subtype and considered one of the most aggressive lyrnphomas with worse prognosis than other subtypes ofN H L. Despite the great progress over the last several decades, treatment of MCL still has troubles in survival, relapse, and drug resistance.
To the Editor： Mantle cell lymphoma （MCL） is a non-Hodgkin＇s lymphoma （NHL） subtype and considered one of the most aggressive lyrnphomas with worse prognosis than other subtypes ofN H L. Despite the great progress over the last several decades, treatment of MCL still has troubles in survival, relapse, and drug resistance.
